Web Results

clinicaltrials.gov/ct2/show/NCT04598919

Scarring of the lung, termed pulmonary fibrosis (PF), is a chronic, progressive, and usually fatal disorder. While two anti-fibrotic drugs have recently been approved for treating PF of unknown cause (idiopathic pulmonary fibrosis or IPF), neither drug is curative, and nearly 40% of patients stop taking the prescribed drug within a year because of side effects.

medicaldialogues.in/news/industry/pharma/bdr-pharma-unveils-idiopathic...

IPF is a lung disorder where there is scarring of the lungs due to an unknown cause, BDR Pharmaceuticals said in a statement. "We are proud to launch the generic version of the drug for lung fibrosis in India especially during a time when there is an ardent need of the medicine for COVID-19 patients," BDR Pharmaceuticals CMD Dharmesh Shah said.

www.sciencedirect.com/science/article/pii/S1359644620303767

The two approved IPF drugs also perform inconsistently in these assays, making the preclinical evaluation of combination therapies particularly difficult , a limitation exacerbated by the overall tolerability burden involved. Table 2. Examples of compounds that have failed in development (Phase II/III), but have been progressed based on ...

www.news-medical.net/news/20200806/Powerful-treatment-for-IPF-stops-dangerous...

A pre-clinical study led by scientists at Cincinnati Children's demonstrates that in mice the drug barasertib reverses the activation of fibroblasts that cause dangerous scar tissue to build up in ...

www.webmd.com/lung/qa/what-medications-may-keep-your-idiopathic-pulmonary...

two drugs may help prevent new scarring from forming in your lungs, which is the cause of your breathing troubles. nintedanib (ofev) and pirfenidone (esbriet) block a process in your body that leads

rtmagazine.com/disorders-diseases/chronic-pulmonary-disorders/pulmonary...

Two drugs to reduce the scarring of the lungs that occurs in patients with idiopathic pulmonary fibrosis (IPF) appear to increase longevity and decrease hospitalizations, according to new research published online in the American Journal of Respiratory and Critical Care Medicine. In “Clinical Effectiveness of the Anti-Fibrotic Medications for Idiopathic Pulmonary Fibrosis,” lead author ...

www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30866-8/fulltext

Idiopathic pulmonary fibrosis is a prototype of chronic, progressive, and fibrotic lung disease. Healthy tissue is replaced by altered extracellular matrix and alveolar architecture is destroyed, which leads to decreased lung compliance, disrupted gas exchange, and ultimately respiratory failure and death. In less than a decade, understanding of the pathogenesis and management of this disease ...

www.oxygenconcentratorstore.com/blog/treating-idiopathic-pulmonary-fibrosis...

Even with the FDA approvals of these two drugs, doctors are still sticking to the previous ways of helping patients to deal with IPF. Pulmonary Rehabilitation Supervised by a respiratory therapist, patients are guided through a specific type of exercise program, which targets the use of the lungs.

medicalxpress.com/news/2019-01-first-in-human-trial-senolytic-drugs.html

"No drug therapies, including the available anti-fibrotic drugs, have ever shown to stabilize, let alone improve, an IPF patient's six-minute walk distance," Dr. Nambiar said.

www.verywellhealth.com/idiopathic-pulmonary-fibrosis-treatments-and-prognosis...

Medications for Idiopathic Pulmonary Fibrosis Tyrosine Kinase Inhibitors . In October of 2014, two medications became the first drugs approved by the FDA specifically for the treatment of idiopathic pulmonary fibrosis. These medications, pirfenidone and nintedanib, target enzymes called tyrosine kinase and work by reducing fibrosis (antifibrotics).